Atlas FDA

Esprit™ BTK Everolimus Eluting Resorbable Scaffold System

FDA premarket approval P230036/S015 · decided 2025-09-26

Approval details

PMA number
P230036
Supplement
S015
Supplement type
30-Day Notice
Supplement reason
Process Change - Manufacturer/Sterilizer/Packager/Supplier
Trade name
Esprit™ BTK Everolimus Eluting Resorbable Scaffold System
Generic name
Scaffold, infrapopliteal, absorbable
Applicant
ABBOTT MEDICAL
Date received
2025-08-29
Decision date
2025-09-26
Days to decision
28 days
Decision code
OK30
Product code
NXW
Advisory committee
Cardiovascular
Expedited review
No
Location
Santa Clara, CA
Statement
to update the endotoxin sampling quantity and testing frequency

Class III intelligence, same tools

PMAs share the API, exports and alerts with 510(k) data - watch an applicant and hear about every approval.

510(k) clearances by this applicant

RecordFirmDate
EnSite™ X EP System (K262006)Abbott Medical2026-07-15
Amplatzer TorqVue Exchange System (K261631)Abbott Medical2026-06-17
OPTIS Mobile Next Imaging System (1014932); OPTIS Integrated Next Imaging System (1014933); Ultreon 3.0 Software Upgrade Kit (ULTR300001) (K253459)ABBOTT MEDICAL2026-04-24
EnSite™ X EP System (K260212)ABBOTT MEDICAL2026-04-20
Disposable Radiofrequency Cannula (K253907)ABBOTT MEDICAL2026-04-16
Amplatzer™ Trevisio™ Intravascular Delivery System; 9-ATV06F45/609-ATV07F45/609-ATV07F45/809-ATV08F45/609-ATV08F45/809-ATV09F45/809-ATV10F45/809-ATV12F45/80 (K260499)ABBOTT MEDICAL2026-03-13
Armada™ 14 NC PTA Catheter (K252512)ABBOTT MEDICAL2026-02-13
Assert-IQ (DM5100) (K253516)ABBOTT MEDICAL2025-12-18